The Effect of Silymarin Flavonolignans and Their Sulfated Conjugates on Platelet Aggregation and Blood Vessels Ex Vivo
暂无分享,去创建一个
V. Křen | K. Valentová | L. Petrásková | P. Mladěnka | Lenka Applová | J. Pourová | J. Karlíčková | M. Vopršálová | Thomas Migkos | K. Macáková | D. Biedermann | R. Bentanachs | Marcel Hrubša | V. Tvrdý
[1] L. Nováková,et al. Two flavonoid metabolites, 3,4-dihydroxyphenylacetic acid and 4-methylcatechol, relax arteries ex vivo and decrease blood pressure in vivo. , 2018, Vascular pharmacology.
[2] V. Křen,et al. Sulfated Metabolites of Flavonolignans and 2,3-Dehydroflavonolignans: Preparation and Properties , 2018, International journal of molecular sciences.
[3] B. Razavi,et al. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review , 2018, Phytotherapy research : PTR.
[4] N. Amiri,et al. Effects of silymarin on metabolic syndrome: a review. , 2018, Journal of the science of food and agriculture.
[5] N. Lin,et al. Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[6] J. Vacek,et al. Metabolism of flavonolignans in human hepatocytes , 2018, Journal of pharmaceutical and biomedical analysis.
[7] M. Bijak,et al. Flavonolignans reduce the response of blood platelet to collagen. , 2018, International journal of biological macromolecules.
[8] P. Mladěnka,et al. The isoflavonoid tectorigenin has better antiplatelet potential than acetylsalicylic acid. , 2017, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[9] V. Křen,et al. The silymarin composition… and why does it matter??? , 2017, Food research international.
[10] M. Bijak,et al. Flavonolignans inhibit the arachidonic acid pathway in blood platelets , 2017, BMC Complementary and Alternative Medicine.
[11] P. Mouthuy,et al. European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS) , 2017, Redox biology.
[12] David S. Ramirez,et al. L-type calcium channel antagonism - Translation from in vitro to in vivo. , 2017, Journal of pharmacological and toxicological methods.
[13] M. Bijak,et al. Flavonolignans inhibit ADP induced blood platelets activation and aggregation in whole blood. , 2017, International journal of biological macromolecules.
[14] J. Weisel,et al. Role of red blood cells in haemostasis and thrombosis , 2017, ISBT science series.
[15] L. Nováková,et al. Flavonoid metabolite 3-(3-hydroxyphenyl)propionic acid formed by human microflora decreases arterial blood pressure in rats. , 2016, Molecular nutrition & food research.
[16] P. Mladěnka,et al. Antiplatelet Effects of Flavonoids Mediated by Inhibition of Arachidonic Acid Based Pathway , 2015, Planta Medica.
[17] G. Ribaudo,et al. Semi-synthetic derivatives of natural isoflavones from Maclura pomifera as a novel class of PDE-5A inhibitors. , 2015, Fitoterapia.
[18] V. Křen,et al. Pharmacokinetics of pure silybin diastereoisomers and identification of their metabolites in rat plasma , 2015 .
[19] C. Caballero-George,et al. Modulation of Calcium Signaling of Angiotensin AT1, Endothelin ETA, and ETB Receptors by Silibinin, Quercetin, Crocin, Diallyl Sulfides, and Ginsenoside Rb1 , 2014, Planta Medica.
[20] V. Křen,et al. Preparatory separation of the silymarin flavonolignans by Sephadex LH-20 gel , 2014 .
[21] V. Křen,et al. Chemistry of silybin. , 2014, Natural product reports.
[22] B. Demirci,et al. Silymarin Improves Vascular Function of Aged Ovariectomized Rats , 2014, Phytotherapy research : PTR.
[23] V. Křen,et al. Bioavailability of silymarin flavonolignans: drug formulations and biotransformation , 2013, Phytochemistry Reviews.
[24] K. Abnous,et al. Protective Effect of Silymarin against Acrolein-Induced Cardiotoxicity in Mice , 2012, Evidence-based complementary and alternative medicine : eCAM.
[25] L. Calani,et al. Absorption and metabolism of milk thistle flavanolignans in humans. , 2012, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[26] B. Saeed,et al. ADJUVANT USE OF SILYMARIN IN PATIENTS WITH HYPERTENSION AND MICROALBUMINURIA , 2012 .
[27] E. Heidarian,et al. Effect of silymarin on liver phoshpatidate phosphohydrolase in hyperlipidemic rats , 2012 .
[28] V. Křen,et al. Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP-glucuronosyltransferases , 2011, Xenobiotica; the fate of foreign compounds in biological systems.
[29] S. Baboota,et al. Oil based nanocarrier for improved oral delivery of silymarin: In vitro and in vivo studies. , 2011, International journal of pharmaceutics.
[30] G. Li Volti,et al. Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice , 2011, Cardiovascular Diabetology.
[31] G. Jadhav,et al. Antihypertensive effect of Silymarin on DOCA salt induced hypertension in unilateral nephrectomized rats , 2011, Oriental Pharmacy and Experimental Medicine.
[32] V. Křen,et al. Large-scale separation of silybin diastereoisomers using lipases , 2010 .
[33] S. J. Schrieber,et al. Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C , 2010, Journal of clinical pharmacology.
[34] M. Metwally,et al. Effects of silymarin on lipid metabolism in rats. , 2009 .
[35] N. El-Shitany,et al. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[36] Shaun P Jackson,et al. The growing complexity of platelet aggregation. , 2007, Blood.
[37] V. Křen,et al. Silybin and silymarin--new and emerging applications in medicine. , 2007, Current medicinal chemistry.
[38] V. Křen,et al. New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity. , 2006, Bioorganic & medicinal chemistry.
[39] Y. H. Han,et al. Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process. , 2004, Journal of pharmaceutical and biomedical analysis.
[40] Song-Kyu Park,et al. Silymarin inhibits TNF‐α‐induced expression of adhesion molecules in human umbilical vein endothelial cells , 2003, FEBS letters.
[41] V. Křen,et al. Chemoenzymatic preparation of silybin beta-glucuronides and their biological evaluation. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[42] N. Škottová,et al. Dietary silymarin improves removal of low density lipoproteins by the perfused rat liver. , 1998, Acta Universitatis Palackianae Olomucensis Facultatis Medicae.
[43] J. Ulrichová,et al. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. , 1998, Planta medica.
[44] C. Ryu,et al. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets. , 1997, Biochemical pharmacology.
[45] H. de Groot,et al. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. , 1996, Life sciences.
[46] D. Su,et al. Protective effects of silybin and tetrandrine on the outcome of spontaneously hypertensive rats subjected to acute coronary artery occlusion. , 1993, International journal of cardiology.
[47] Y. Rui. Advances in pharmacological studies of silymarin. , 1991, Memorias do Instituto Oswaldo Cruz.